FDA Adverse Event Injury Summary report: N

UNKNOWN AQM DEVICE

MDR report key: 24022095 · Received January 9, 2026

Report

Report Number
1226420-2026-00002
Event Type
Injury
Date Received
January 9, 2026
Date of Event
August 22, 2023
Report Date
January 9, 2026
Manufacturer
MEDTRONIC ADVANCED ENERGY (SALIENT)
Product Code
GEI
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
AS
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

A2) PATIENT AGE IS THE MEAN VALUE OF PATIENTS IN THE STUDY. A3) PATIENT GENDER IS THE MAJORITY VALUE OF PATIENTS IN THE STUDY. G4) 510(K) IS DEPENDENT UPON THE DEVICE MODEL NUMBER AND IS THEREFORE, UNAVAILABLE. H3) NO PARTS HAVE BEEN RECEIVED BY THE MANUFACTURER FOR EVALUATION. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

KLEINIG, T. J., ABOU-HAMDEN, A., LAIDLAW, J., CHURILOV, L., KELLNER, C. P., WU, T., MOCCO, J., LAU, H., ADAMIDES, A., KAVAR, B., DIMOU, J., CRANEFIELD, J., MCDONALD, A., PLUMMER, S., DAVIS, S., & CAMPBELL, B. C. (2023). EARLY MINIMALLY INVASIVE INTRACEREBRAL HEMORRHAGE EVACUATION: A PHASE 2A FEASIBILITY, SAFETY, AND PROMISE OF SURGICAL EFFICACY STUDY. JOURNAL OF NEUROINTERVENTIONAL SURGERY, 16(6), 555¿558. HTTPS://DOI.ORG/10.1136/JNIS-2023-020446. ABSTRACT BACKGROUND SURGICAL TREATMENT OF INTRACEREBRAL HEMORRHAGE (ICH) IS UNPROVEN, ALTHOUGH META-ANALYSES SUGGEST THAT BOTH EARLY CONVENTIONAL SURGERY WITH CRANIOTOMY AND MINIMALLY INVASIVE SURGERY (MIS) MAY BE BENEFICIAL. WE AIMED TO DEMONSTRATE THE SAFETY, FEASIBILITY, AND PROMISE OF EFFICACY OF EARLY MIS FOR ICH USING THE AURORA SURGISCOPE AND EVACUATOR. METHODS WE PERFORMED A PROSPECTIVE, SINGLE ARM, PHASE ILA SIMON'S TWO STAGE DESIGN STUDY AT TWO STROKE CENTERS (10 PATIENTS WITH SUPRATENTORIAL ICH VOLUMES 2:20 ML AND NATIONAL INSTITUTES OF HEALTH STROKE SCALE (NIHSS) SCORE OF 2:6, AND SURGERY COMMENCING 12 HOURS AFTER ONSET). POSITIVE OUTCOME WAS DEFINED AS; -:50% 24 HOUR ICH VOLUME REDUCTION, WITH THE SAFETY OUTCOME LACK OF SIGNIFICANT ICH REACCUMULATION. RESULTS FROM DECEMBER 2019 TO JULY 2020, WE ENROLLED 10 PATIENTS AT TWO AUSTRALIAN COMPREHENSIVE STROKE CENTERS, MEDIAN AGE 70 YEARS (IQR 65 -74), NIHSS SCORE 19 (IQR 19-29), ICH VOLUME 59 ML (IQR 25-77), AT A MEDIAN OF 227 MIN (IQR 175-377) POST-ONSET. WAS COMMENCED AT A MEDIAN TIME OF 531 MIN (IQR 437-628) POST-ONSET, HAD A MEDIAN DURATION OF 98 MIN (IQR 77-11 0), WITH A MEDIAN IMMEDIATE POSTOPERATIVE HEMATOMA EVACUATION OF 70% (IQR 67-80%). A POSITIVE OUTCOMEWAS ACHIEVED IN 5/5 FIRST STAGE PATIENTS AND IN 4/5 SECOND STAGE PATIENTS. ONE PATIENT DEVELOPED SIGNIFICANT 24 HOUR ICH REACCUMULATION; OTHERWISE, 24 HOUR STABILITY WAS OBSERVED (MEDIAN REDUCTION 71 % (IQR 61-80), 5/9 PATIENTS 15 ML RESIDUAL). THREE PATIENTS DIED, UNRELATED TO SURGERY. THERE WERE NO SURGICAL SAFETY CONCERNS. AT 6 MONTHS, THE MEDIAN MODIFIED RANKIN SCALE SCORE WAS 4 (IQR 3-6) WITH 30% ACHIEVING A SCORE OF 0-3. CONCLUSION IN THIS STUDY, EARLY ICH MIS USING THE AURORA SURGISCOPE AND EVACUATOR APPEARED TO BE FEASIBLE AND SAFE, WARRANTING FURTHER EXPLORATION. 1. ONE PATIENT DEVELOPED SIGNIFICANT 24 HOUR ICH REACCUMULATION; OTHERWISE, 24 HOUR STABILITY WAS OBSERVED (MEDIAN REDUCTION 71 % (IQR 61-80), 5/9 PATIENTS 15 ML RESIDUAL).

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
81611 UNKNOWN AQM DEVICE ELECTROSURGICAL, CUTTING & COAGULATION & ACCES GEI MEDTRONIC ADVANCED ENERGY (SALIENT) MAE UNK AQM DEV

Patients

Seq Age Sex Outcome Treatment
1 70 YR Male Other